Microbiome therapies: why we are not there yet

Microbiome therapies have the potential to revolutionise our approach to medicine, but until now, a lack of standardisation and regulation has hampered clinical development. Here, Chrysi Sergaki and Jack Hassall from the National Institute for Biological Standards and Control discuss how they are developing reference reagents to standardise analysis of microbiome samples, and how research is now moving towards the development of more targeted microbiome‐based therapeutics.